AbCellera Biologics Inc.
ABCL
$4.24
-$0.23-5.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.62M | -34.21M | -51.11M | -36.93M | -40.61M |
| Total Depreciation and Amortization | 6.61M | -18.10M | 38.30M | 38.04M | 6.77M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.00M | 29.41M | -10.34M | -23.04M | 19.12M |
| Change in Net Operating Assets | 10.46M | 14.90M | -5.73M | -8.04M | -26.98M |
| Cash from Operations | -11.55M | -8.00M | -28.88M | -29.97M | -41.71M |
| Capital Expenditure | -10.64M | -15.63M | -18.52M | -20.11M | -24.14M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.57M | 51.33M | 22.21M | 72.21M | 54.05M |
| Cash from Investing | 7.94M | 35.70M | 3.70M | 52.10M | 29.91M |
| Total Debt Issued | 6.15M | 5.90M | 3.10M | 2.37M | 3.02M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 227.00K | 461.00K | -- |
| Repurchase of Common Stock | -- | -1.58M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -178.00K | -177.00K | -184.00K | -183.00K | -185.00K |
| Cash from Financing | 5.97M | 4.14M | 3.15M | 2.65M | 2.83M |
| Foreign Exchange rate Adjustments | 590.00K | -2.16M | 367.00K | -43.00K | -781.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.94M | 29.69M | -21.67M | 24.74M | -9.75M |